


Cancer-Targeting Compound 1

| | |
|--------------------|---|
| Cat. No.: | HY-U00300 |
| CAS No.: | 1007581-62-5 |
| Molecular Formula: | C ₁₅ H ₁₃ N ₃ O ₂ S |
| Molecular Weight: | 299.35 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |



BIOLOGICAL ACTIVITY

| | |
|-------------|--|
| Description | Cancer-Targeting Compound 1 is used in the research of hormone-related cancer, extracted from patent WO 2008021331 A2. |
| In Vitro | Cancer-Targeting Compound 1 is useful for the research of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Thomas, Joseph, et al. OXAZOLIDONE DERIVATIVES AS PR MODULATORS. WO 2008021331 A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA